Pacer Advisors
ALXN

Pacer Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Pacer Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-81,332
Closed -$14.9M – 1498
2021
Q2 		$14.9M Buy
81,332
+24,349
+43% +$4.18M 0.21% 70
2021
Q1 		$8.71M Sell
56,983
-1,412
-2% -$218K 0.15% 103
2020
Q4 		$9.12M Sell
58,395
-13,819
-19% -$1.78M 0.17% 88
2020
Q3 		$8.26M Sell
72,214
-1,429
-2% -$154K 0.18% 96
2020
Q2 		$8.27M Buy
73,643
+18,181
+33% +$1.93M 0.17% 105
2020
Q1 		$5.74M Buy
55,462
+38,030
+218% +$3.73M 0.12% 68
2019
Q4 		$1.89M Sell
17,432
-23,553
-57% -$2.52M 0.09% 283
2019
Q3 		$4.01M Buy
40,985
+4,433
+12% +$500K 0.09% 228
2019
Q2 		$4.79M Buy
36,552
+4,118
+13% +$531K 0.12% 160
2019
Q1 		$4.38M Buy
+32,434
New +$4.03M 0.12% 149
2018
Q4 		– Sell
-22,495
Closed -$3.13M – 1132
2018
Q3 		$3.13M Buy
22,495
+4,994
+29% +$626K 0.12% 165
2018
Q2 		$2.17M Buy
17,501
+3,070
+21% +$359K 0.1% 241
2018
Q1 		$1.61M Buy
14,431
+1,714
+13% +$205K 0.09% 274
2017
Q4 		$1.52M Buy
12,717
+5,033
+65% +$613K 0.11% 242
2017
Q3 		$1.08M Buy
7,684
+942
+14% +$128K 0.1% 263
2017
Q2 		$820K Buy
6,742
+465
+7% +$54.1K 0.08% 334
2017
Q1 		$761K Buy
6,277
+259
+4% +$33.4K 0.09% 290
2016
Q4 		$736K Buy
6,018
+29
+0.5% +$3.55K 0.1% 218
2016
Q3 		$734K Sell
5,989
-247
-4% -$31.8K 0.11% 195
2016
Q2 		$728K Sell
6,236
-144
-2% -$20.4K 0.11% 179
2016
Q1 		$889K Buy
6,380
+153
+2% +$22.5K 0.2% 98
2015
Q4 		$1.19M Buy
+6,227
New +$1.09M 0.28% 71

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Pacer Advisors's ALXN Position: Q3 2021 in Review

Pacer Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 81,332 shares — an estimated $14.9M sold.

Pacer Advisors first reported a position in ALXN in Q4 2015 and held it in 22 quarters. The position peaked at $14.9M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Pacer Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Pacer Advisors sold 81,332 Alexion Pharmaceuticals shares in Q3 2021, an estimated $14.9M.
  • Pacer Advisors first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 22 quarters.
  • Pacer Advisors's Alexion Pharmaceuticals position peaked at $14.9M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Pacer Advisors's 13F filing for Q3 2021, filed 15 Oct 2021.